Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.

Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E, Palmer S, Riemsma R.

Br J Cancer. 2006 Aug 21;95(4):457-62. Epub 2006 Aug 1. Review.

2.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R.

Health Technol Assess. 2007 Jan;11(2):iii-iv, xv-xviii, 1-179. Review.

3.
4.

Chemotherapy for hormone-refractory prostate cancer.

Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005247. Review.

PMID:
17054249
5.

Which drug combination for hormone-refractory prostate cancer?

Doggrell SA.

Expert Opin Pharmacother. 2005 Apr;6(4):667-70. Review.

PMID:
15934892
6.

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.

J Clin Oncol. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

PMID:
15738542
7.
8.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators.

Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.

PMID:
20888992
9.

Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.

Galli L, Fontana A, Galli C, Landi L, Fontana E, Antonuzzo A, Andreuccetti M, Aitini E, Barbieri R, Di Marsico R, Falcone A.

Br J Cancer. 2007 Dec 17;97(12):1613-7. Epub 2007 Nov 20.

10.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators.

N Engl J Med. 2004 Oct 7;351(15):1502-12.

11.

Future directions in the treatment of androgen-independent prostate cancer.

Petrylak DP.

Urology. 2005 Jun;65(6 Suppl):8-12. Review.

PMID:
15939077
12.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

N Engl J Med. 2004 Oct 7;351(15):1513-20.

13.
14.

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J.

J Clin Oncol. 2008 Nov 10;26(32):5261-8. doi: 10.1200/JCO.2008.16.9524. Epub 2008 Sep 15.

PMID:
18794543
15.

Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

Protheroe A.

Nat Clin Pract Oncol. 2005 Feb;2(2):68-9. No abstract available.

PMID:
16264873
16.

Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.

Font A, Murias A, Arroyo FR, Martin C, Areal J, Sanchez JJ, Santiago JA, Constenla M, Saladie JM, Rosell R.

Ann Oncol. 2005 Mar;16(3):419-24. Epub 2005 Jan 24.

PMID:
15668260
17.

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K.

Cancer. 2006 Mar 1;106(5):1041-6.

18.

[Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].

Batman E, de Wit R.

Ned Tijdschr Geneeskd. 2005 Oct 29;149(44):2442-5. Dutch.

PMID:
16285357
19.

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J, Kumar MS.

Pharmacoeconomics. 2017 Apr;35(4):415-424. doi: 10.1007/s40273-016-0457-1. Review.

PMID:
27770303
20.

[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].

Ferrero JM.

Bull Cancer. 2005 May 1;92(5):425-7. Review. French.

Supplemental Content

Support Center